Biosign Corporate Update

TORONTO, March 15, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) 
("Biosign" or the "Company") today announced the following: 
Changes to the Board of Directors: 
Biosign announces the resignation of directors Mr. Jason Meretsky and Senator 
Alfonse D'Amato, effective immediately. Mr. Meretsky and Senator D'Amato are 
leaving the Board in order to devote time to their other business interests. 
The Board and management wish to sincerely thank both directors for their 
dedicated service. They have helped lead Biosign through a challenging period 
of restructuring and their advice and counsel have been instrumental in 
allowing the Company to succeed. We wish them both great success in all their 
future endeavors. 
Biosign is pleased to announce the appointment of two new directors: 
Dr. Sandeep (Sonny) Kohli is an attending Physician in the Intensive Care 
Department of Oakville Trafalgar Memorial Hospital and Assistant Clinical 
Professor (Adjunct) of Medicine at McMaster University. He is also the Medical 
Director, ACLS, at the Michener Institute for Applied Health Sciences and 
President of Triomi Medical Innovations Inc. From May 2008 to March 2009Dr. 
Kohli was an Astronaut Candidate at the Canadian Space Agency (CSA), where he 
was awarded a Scholarship by the CSA as a Critical Care Medicine fellow to go 
to Johnson Space Center and partake in aerospace medical research activities. 
Dr. Kohli has also been appointed as Medical Director for Biosign. He is 
highly knowledgeable regarding Biosign's Pulsewave™ product, having 
previously served as a medical advisor to BioAnalytics Inc., a Biosign 
distribution partner. 
Mr. Dennis Rygwalski is a senior financial services & technology executive 
recognized for leading best-of-class enterprise IT and bank operations 
organizations. He is currently the founder of D. Rygwalsky & Associates Inc., 
a Tulsa, Oklahoma management consulting firm to the financial services and 
technology sectors. Until 2012 he served as EVP Technology & Chief 
Information Officer for Western Alliance Bancorp, a $7 billion commercial 
multi-bank holding company based in Phoenix, Arizona, and before that he held 
the positions of Chief Technology Officer for the Bank of Oklahoma, a $25 
billion financial services group (2006-2011), head of Finance Industry 
Solutions for Boston-based technology provider Exigen Group (2001-2005), and 
Chief Information Officer for Fleet Boston Financial, a $180 billion 
diversified banking and financial services company acquired by Bank of America 
in 2004 (1988-2001). 
With these appointments, the Board now consists of independent directors Dr. 
Sonny Kohli and Mr. Dennis Rygwalski, along with Chairman John Rizvi and 
Biosign CEO Robert Kaul. 
Biosign CEO Robert Kaul commented: "I would like to personally thank Mr. 
Meretsky and Senator D'Amato for their work on the Board. They have both 
provided our team with outstanding advice and their wisdom has been much 
appreciated. We are pleased to welcome two new Board members. Dr. Sonny Kohli 
is a very passionate, articulate advocate for Biosign's products and we look 
forward to his assistance as we present our products to the medical community. 
Dennis Rygwalski brings to the Company many years of experience as a senior 
technology leader and his advice will be particularly welcome as Biosign grows 
into the U.S. market starting in 2013. I believe that shareholders will be 
well served by the addition of these independent directors." 
Update on Previously-Announced Financing 
With respect to the previously announced additional subscription of 6,000,000 
units of the Company (the "Units") at a purchase price of $0.05 per Unit, 
forming part of the previously- announced private placement (see news release 
issued on December 21, 2012), a tranche of 700,000 Units was completed on 
March 14, 2013 for gross proceeds to the Company of $35,000. The investor has 
not completed the remaining subscription for 4,300,000 Units on the scheduled 
closing date. As a result of the foregoing, the Company reserves all of its 
rights and remedies available under the subscription agreement with the 
investor. 
About Biosign Technologies Inc. 
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled 
health information products. Key applications include the noninvasive 
monitoring of vital signs including blood pressure, pulse rate and breathing 
rate, enhanced with web services. The Company's Pulsewave™ medical device 
technology powers data collection for clinical decision support, self-care, 
wellness and disease management, while it's Healthanywhere™ software suite 
offers industry-leading remote patient monitoring solutions. The Company 
offers a number of cardiovascular screening programs for consumers under its 
Heart Friendly™ brand, including Heart Friendly™ Dentist. For more 
information on Biosign, please visit www.biosign.com 
Forward-Looking Statements 
This release contains forward-looking statements. Forward-looking statements, 
without limitation, may contain the words believes, expects, anticipates, 
estimates, intends, plans, or similar expressions. Forward-looking statements 
are not guarantees of future performance. They involve risks, uncertainties 
and assumptions and Biosign's actual results could differ materially from 
those anticipated. Forward looking statements are based on the opinions and 
estimates of management at the date the statements are made, and are subject 
to a variety of risks and uncertainties and other factors that could cause 
actual events or results to differ materially from those projected in the 
forward-looking statements. In the context of any forward-looking information 
please refer to risk factors detailed in, as well as other information 
contained in, Biosign's filings with Canadian securities regulators 
(www.sedar.com). 
Neither TSX Venture Exchange nor its Regulation Services Provider (as that 
term is defined in policies of the TSX Venture Exchange) accepts 
responsibility for the adequacy or accuracy of this release. 
Biosign Contact Information 
Robert Kaul Chief Executive Officer Biosign Technologies Phone: (416) 218-9800 
ext. 201 Email:ceo@biosign.com   
SOURCE: Biosign Technologies Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/15/c5512.html 
CO: Biosign Technologies Inc.
ST: Ontario
NI: HEA 2575 WNEWS LOAN MNA  
-0- Mar/15/2013 20:01 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.